176 related articles for article (PubMed ID: 34286843)
1. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
Ali AM; P Solans B; Hesseling AC; Winckler J; Schaaf HS; Draper HR; van der Laan L; Hughes J; Fourie B; Nielsen J; Wiesner L; Garcia-Prats AJ; Savic RM
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0079423. PubMed ID: 38112526
[TBL] [Abstract][Full Text] [Related]
3. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
Thee S; Garcia-Prats AJ; Draper HR; McIlleron HM; Wiesner L; Castel S; Schaaf HS; Hesseling AC
Clin Infect Dis; 2015 Feb; 60(4):549-56. PubMed ID: 25362206
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
[TBL] [Abstract][Full Text] [Related]
7. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Galileya LT; Wasmann RE; Chabala C; Rabie H; Lee J; Njahira Mukui I; Hesseling A; Zar H; Aarnoutse R; Turkova A; Gibb D; Cotton MF; McIlleron H; Denti P
PLoS Med; 2023 Nov; 20(11):e1004303. PubMed ID: 37988391
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
[TBL] [Abstract][Full Text] [Related]
9. QT prolongation in the STREAM Stage 1 Trial.
Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
Int J Tuberc Lung Dis; 2022 Apr; 26(4):334-340. PubMed ID: 35351238
[TBL] [Abstract][Full Text] [Related]
10. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
[TBL] [Abstract][Full Text] [Related]
12. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
Abdelwahab MT; Court R; Everitt D; Diacon AH; Dawson R; Svensson EM; Maartens G; Denti P
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0268720. PubMed ID: 33875426
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
15. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.
Bjugård Nyberg H; Draper HR; Garcia-Prats AJ; Thee S; Bekker A; Zar HJ; Hooker AC; Schaaf HS; McIlleron H; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871093
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolones for the treatment of tuberculosis in children.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
